[1]郑宇,谭福柱,任树军△.生髓健骨胶囊对酒精性骨质疏松大鼠血清超氧化物歧化酶及丙二醛的影响[J].中国中医骨伤科杂志,2024,32(11):1-4+10.[doi:10.20085/j.cnki.issn1005-0205.241101]
　ZHENG Yu,TAN Fuzhu,REN Shujun.Effects of Shengsui Jiangu Capsules on Superoxide Dismutase and Malondialdehyde in Serum of Rats with Alcoholic Osteoporosis[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2024,32(11):1-4+10.[doi:10.20085/j.cnki.issn1005-0205.241101]
点击复制

生髓健骨胶囊对酒精性骨质疏松大鼠血清超氧化物歧化酶及丙二醛的影响()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第32卷
期数:
2024年11期
页码:
1-4+10
栏目:
实验研究
出版日期:
2024-11-15

文章信息/Info

Title:
Effects of Shengsui Jiangu Capsules on Superoxide Dismutase and Malondialdehyde in Serum of Rats with Alcoholic Osteoporosis
文章编号:
1005-0205(2024)11-0001-04
作者:
郑宇1; 谭福柱2; 任树军2△
1黑龙江中医药大学研究生院(哈尔滨,150040)
2黑龙江中医药大学附属第一医院
Author(s):
ZHENG Yu1; TAN Fuzhu2; REN Shujun2△
1Graduate School of Heilongjiang University of Chinese Medicine,Harbin 150040,China; 2First Affiliated Hospital of Heilongjiang University of Chinese Medicine,Harbin 150040,China.
关键词:
生髓健骨胶囊;  酒精性骨质疏松;  超氧化物歧化酶;  丙二醛
Keywords:
Shengsui Jiangu capsule;  alcoholic osteoporosis;  superoxide dismutase;  malondialdehyde
分类号:
R-33
DOI:
10.20085/j.cnki.issn1005-0205.241101
文献标志码:
A
摘要:
目的:研究酒精性骨质疏松(AOP)大鼠血清中超氧化物歧化酶(SOD)、丙二醛(MDA)的变化及中药生髓健骨胶囊对其影响,探讨生髓健骨胶囊对酒精性骨质疏松症大鼠模型的中药防治作用机理。方法:选取120只SD大鼠,随机分成4组(每组30只),分别命名为空白对照组、模型组、西药对照组和中药干预组。除空白对照组外,其他3组通过白酒灌胃法建立酒精性骨质疏松模型。西药对照组给予碳酸钙片与阿法D3混悬液灌胃治疗,中药干预组给予生髓健骨胶囊与0.9%生理盐水混悬液灌胃治疗。于造模第8,12,16周末取材,通过分光光度法测定大鼠血清中超氧化物歧化酶和丙二醛的含量。结果:检测造模干预8,12,16周后超氧化物歧化酶及丙二醛指标变化,模型组血清中超氧化物歧化酶含量低于空白对照组,丙二醛含量高于空白对照组,且差异有统计学意义(P<0.01); 西药对照组和中药干预组的血清超氧化物歧化酶水平高于模型组,而丙二醛含量则低于模型组,差异有统计学意义(P<0.05),表明两组干预均能提高超氧化物歧化酶活性并降低丙二醛水平; 中药干预组在预防酒精性骨质疏松方面的效果优于西药干预组,差异有统计学意义(P<0.05)。结论:血清中超氧化物歧化酶及丙二醛参与了大鼠酒精性骨质疏松症的病理进程,而生髓健骨胶囊可以调节酒精性骨质疏松症大鼠血清中超氧化物歧化酶及丙二醛含量,这是预防骨质疏松症的机制之一。
Abstract:
Objective:To study on the changes of superoxide dismutase(SOD)and malondialdehyde(MDA)in the serum of rats with alcoholic osteoporosis(AOP)and the effects of the traditional Chinese medicine Shengsui Jiangu capsules on them,and to explore the mechanism of the therapeutic efficacy of Shengsui Jiangu capsules on the AOP rat model.Methods:120 SD rats were selected,and were divided into four groups,each consisting of 30 rats.The groups were named as follows:blank control group,model group,Western medicine control group,and Chinese medicine intervention group.Except for the blank control group,the alcohol-induced osteoporosis models were established in other three groups by gavage with white liquor.After the modeling,the Western medicine control group was treated with a suspension made from calcium carbonate tablets and Alfa D3(a form of vitamin D3); the Chinese medicine intervention group was treated with a suspension made from Shengsui Jiangu capsules and 0.9% saline solution.At the end of weeks 8,12,and 16 post-modeling,samples were taken,and the levels of SOD and MDA in the rat serum were determined using spectrophotometry.Results:The study monitored the variations in SOD and MDA indicators after 8,12,and 16 weeks of intervention.The content of SOD in serum of model group was lower than that of blank control group,and the content of MDA was higher than that of blank control group,and the difference was statistically significant(P<0.01).In terms of serum SOD levels,both the Western medicine control group and the Chinese medicine intervention group had higher levels than that of the model group,and the MDA levels of the Western medicine control group and the Chinese medicine intervention group were lower than that of the model group,with statistically significant differences(P<0.05).It showed that both group interventions increased SOD activity and decreased MDA levels.Additionally,the Chinese medicine intervention group showed a more pronounced effect in preventing alcohol-induced osteoporosis than that of the Western medicine control group,with statistically significant difference(P<0.05).Conclusion:SOD and MDA in serum are involved in the pathological process of alcoholic osteoporosis,and Shengsui Jiangu capsule can regulate the content of SOD and MDA in serum of AOP rats,which is one of the mechanisms for preventing osteoporosis.

参考文献/References:

[1] 沈霖,杨艳萍,谢晶,等.国人原发性骨质疏松症诊断标准研究[J].中国中医骨伤科杂志,2003,11(2):3-6.
[2] 胡细连.酒精性骨质疏松的研究现况分析[J].中外医学研究,2017,15(17):162-164.
[3] 黄宏兴,王广伟,王高峰.饮酒与骨质疏松症[J].中国骨质疏松杂志,2010,16(7):533-537.
[4] 张洪然,杨冬晗,张文龙,等.饮酒对骨质疏松症发生的影响[J].中华骨质疏松和骨矿盐疾病杂志,2020,13(4):374-380.
[5] 任树军,于雪峰,孙贵才,等.酒精性骨质疏松症发病机制的研究进展[J].中国骨质疏松杂志,2008,14(8):601-604.
[6] REN S J,XING G L,HU N W,et al.Bushen-Jianpi-Yiqi therapy prevents alcohol-induced osteoporosis in rats[J].Am J Ther,2016,23(5):e1135-e1142.
[7] 陈瀚宇,徐颖鹏,李鼎鹏,等.RANK/RANKL/OPG系统在骨性关节炎与骨质疏松相关性中的作用机制[J].中国中医骨伤科杂志,2019,27(1):86-88.
[8] 林远方,曹亚飞,卿茂盛,等.绝经后妇女活性氧与成骨细胞的关系[J].中医正骨,2007,19(7):9-10.
[9] 孟东方,李慧英,王韬,等.补骨脂干预兔激素性股骨头坏死空骨陷窝的影响[J].中华中医药杂志,2015,30(4):1314-1315.
[10] 赵容山,梁伟坚,邓炜聪,等.姜黄素通过抗氧化应激保护成骨细胞功能的作用机制研究[J].天然产物研究与开发,2022,34(8):1311-1318.
[11] 郭鹏,沈维高,刘艳波,等.牛磺酸对早期糖尿病肾病大鼠NO,MDA和CAT的影响[J].北华大学学报(自然科学版),2003,4(2):133-134.
[12] 屈雅娟,张敬芳,孙旗,等.灯盏细辛联合依帕司他对糖尿病肾病大鼠肾皮质中CAT-SOD-MDA表达的影响[J].中医药信息,2023,40(10):41-45.
[13] ARORA M K,SARUP Y,TOMAR R,et al.Amelioration of diabetes-induced diabetic nephropathy by aloe vera:implication of oxidative stress and hyperlipidemia[J].J Diet Suppl,2019,16(2):227-244.
[14] 赵志强,阎晓霞.中药补肾法改善原发性骨质疏松症临床症状的研究[J].中国骨质疏松杂志,2018,24(3):371-375.
[15] 吴鑫宇,朱洁宜,李冀.骨质疏松症的中医临床方药研究进展[J].中医药学报,2013,41(4):128-129.
[16] 任树军,梁彦林,王墉琦,等.生髓健骨胶囊对酒精性骨质疏松大鼠Wnt信号通路的影响[J].时珍国医国药,2020,31(3):579-582.
[17] 董万涛,吕泽斌,宋敏,等.从脾肾论治骨质疏松症的神经-内分泌-免疫网络平衡机制[J].中国骨质疏松杂志,2015,21(11):1416-1419.
[18] 张旭桥,张信成,仇湘中,等.生骨胶囊对骨质疏松大鼠骨组织骨保护素及核因子κB受体活化因子配基表达的影响[J].中国中医骨伤科杂志,2020,28(8):21-25.
[19] 任树军,刘俊桐,于长江,等.生髓健骨胶囊对酒精性骨质疏松大鼠TNF-α、TGF-β1和空骨陷窝的影响[J].海南医学院学报,2022,28(3):187-191.
[20] 任树军,于长江,梁彦林,等.生髓健骨胶囊对酒精性骨质疏松大鼠血清学指标的影响[J].中国中医骨伤科杂志,2021,29(7):21-24.
[21] 赵金龙,曾令烽,梁桂洪,等.基于信号通路的中药有效成分治疗骨质疏松机制研究进展[J].中草药,2020,51(23):6087-6088.
[22] 董群伟,陈志峰,孙奋勇.牛膝脱皮甾酮促进去卵巢大鼠间充质干细胞的增殖[J].广东医学,2010,31(1):61-63.
[23] 任树军,高伟,于长江,等.生髓健骨胶囊对酒精性骨质疏松大鼠骨转换影响的研究[J].海南医学院学报,2022,28(18):1361-1366.

备注/Memo

备注/Memo:
基金项目:黑龙江省自然科学基金联合引导项目(LH2020H086)
黑龙江省中医药管理局项目(ZHY2022-142)
△通信作者 E-mail:15244603358@163.com
更新日期/Last Update: 2024-11-05